Arcus Biosciences (RCUS) Depreciation & Amortization (CF) (2017 - 2026)

Arcus Biosciences' Depreciation & Amortization (CF) history runs 10 years deep, the most recent figure standing at $2.0 million for Q1 2026.

• On a quarterly basis, Depreciation & Amortization (CF) fell 33.33% year-over-year to $2.0 million in Q1 2026; TTM through Mar 2026 was $9.0 million, a 10.0% decrease from a year earlier, with the FY2025 full-year figure at $10.0 million, changed 0.0% from the prior year.
• Depreciation & Amortization (CF) fell to $2.0 million in Q1 2026 per RCUS's latest filing, from $3.0 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $3.0 million in Q4 2023 and bottomed at $1.0 million in Q1 2022.
• The 5-year median for Depreciation & Amortization (CF) is $2.0 million (2022), against an average of $2.1 million.
• Biggest YoY gain for Depreciation & Amortization (CF) was 200.0% in 2023; the steepest drop was 50.0% in 2023.
• Year by year, Depreciation & Amortization (CF) stood at $1.0 million in 2022, then soared by 200.0% to $3.0 million in 2023, then changed by 0.0% to $3.0 million in 2024, then changed by 0.0% to $3.0 million in 2025, then tumbled by 33.33% to $2.0 million in 2026.
• Per Business Quant, the three latest RCUS Depreciation & Amortization (CF) figures stand at $2.0 million (Q1 2026), $3.0 million (Q4 2025), and $2.0 million (Q3 2025).